Neurological toxicity during metastatic melanoma treatment with fotemustine.
Fotemustine is a cytotoxic drug belonging to the group of nitrosourea derivatives, and is used in the treatment of metastatic melanoma, particularly when secondary brain lesions are present. We report the case of a female patient in partial response following 10 courses of fotemustine and featuring a rapidly progressing mental impairment. The clinical and radiological patterns were consistent with a fotemustine-related toxic encephalopathy, as described previously in a recent report. The physician should be aware of this neurological complication of fotemustine, so that it may be recognized early and not attributed erroneously to tumour evolution.
Khalil
Zakia
Z
Pageot
Nicolas
N
Carlander
Bertrand
B
Guillot
Bernard
B
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D005260:Female; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000009:adverse effects* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; C054368:fotemustine